8-K: Gyre Therapeutics' Hydronidone Achieves Primary Endpoint in Phase 3 Liver Fibrosis Trial

Gyre Therapeutics announces its lead compound, Hydronidone, met the primary endpoint in a pivotal Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B in China.

Summary

• Gyre Therapeutics' Hydronidone (F351) met the primary endpoint in a Phase 3 trial for treating liver fibrosis in patients with chronic hepatitis B (CHB) in China.
• The 52-week trial involved 248 patients across 39 hospitals in China, randomized to receive Hydronidone (270 mg/day) or placebo, along with entecavir antiviral therapy.
• A statistically significant proportion of patients receiving Hydronidone achieved a 1-stage regression in liver fibrosis compared to placebo (52.85% vs. 29.84%, P=0.0002).
• Hydronidone was well-tolerated, with comparable serious adverse events (4.88% vs. 6.45% for placebo) and no discontinuations due to adverse events.
• Gyre plans to submit a New Drug Application (NDA) to China's NMPA in Q3 2025 for accelerated approval.
• A U.S. Phase 2 trial in MASH-associated liver fibrosis is expected to begin in 2H 2025.

Sentiment

Score: 8

Explanation: The document presents positive Phase 3 trial results, indicating a significant step forward for Hydronidone in treating liver fibrosis. The drug's efficacy and safety profile, along with plans for regulatory submissions and further trials, contribute to a positive outlook.

Positives

• Hydronidone achieved statistically significant fibrosis regression compared to placebo in the Phase 3 trial (P=0.0002).
• The drug was well-tolerated, with a comparable incidence of serious adverse events to placebo and no discontinuations due to adverse events.
• A key secondary endpoint of inflammation improvement was also met (P=0.0246).
• Gyre has Breakthrough Therapy Designation from China's NMPA.
• The company plans to submit an NDA in Q3 2025, potentially leading to first-in-class approval.
• A U.S. Phase 2 trial in MASH-associated liver fibrosis is planned, expanding the drug's potential application.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the timing and outcome of regulatory filings and approvals.
• Clinical trial results may not be predictive of future outcomes.
• Competition from other products and general economic conditions could impact results.
• The company's ability to raise additional capital is a potential risk.

Future Outlook

Gyre plans to submit an NDA to China's NMPA in Q3 2025, seeking accelerated approval for Hydronidone in CHB fibrosis. The company also plans to initiate a Phase 2 trial in the U.S. for MASH-associated liver fibrosis in the second half of 2025.

Management Comments

• Han Ying, Ph.D., CEO of Gyre Therapeutics, stated that the Phase 3 results represent a major step forward for Gyre and for millions of Chinese patients living with CHB fibrosis.
• Prof. Lungen Lu, M.D., lead principal investigator, said that Hydronidone has the potential to transform the treatment landscape and offer new hope to patients facing the serious risks of cirrhosis, liver failure, and hepatocellular carcinoma.

Industry Context

CHB remains the leading cause of liver fibrosis in China, and currently no approved anti-fibrotic therapies exist for this population. Hydronidone is uniquely positioned to address this significant and urgent unmet medical need. The company is also expanding into the MASH market in the U.S., which is significantly larger than the CHB market.

Comparison to Industry Standards

• Rezdiffra (Madrigal) is the first FDA-approved therapy for MASH and sets a benchmark for the industry.
• Hydronidone offers a fibrosis-first approach, acting directly on fibrotic tissue, and is the only agent with a demonstrated focus on F4 (cirrhotic) patients.
• Unlike metabolic agents, Hydronidone is designed to be complementary, potentially used as an add-on alongside metabolic agents.
• Comparator data sourced from published studies and company press releases (e.g., Madrigal, Viking, Akero, 89bio, Lilly, Novo Nordisk, Boehringer Ingelheim) show differences in disease, design, and population that limit direct comparison.

Stakeholder Impact

• Shareholders: Positive trial results may increase shareholder value.
• Patients: Hydronidone offers a potential new treatment option for liver fibrosis.
• Employees: Successful development and commercialization could lead to job growth.
• Suppliers: Increased demand for Hydronidone may benefit suppliers.
• Creditors: Positive results may improve the company's creditworthiness.

Next Steps

• Submit primary results for publication in a peer-reviewed journal.
• Present full trial results at a future medical congress.
• File an NDA with China's NMPA in the third quarter of 2025.
• File an investigational new drug (IND) application in the third quarter of 2025.
• Initiate a Phase 2 trial in the U.S. evaluating Hydronidone for the treatment of MASH-associated fibrosis in the second half of 2025.

Key Dates

Keywords

Hydronidone, Liver Fibrosis, CHB, MASH, Phase 3 Trial, Gyre Therapeutics, NMPA, NDA, Clinical Trial, Fibrosis Regression